Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Simpson

Interventional Cardiology Pinehurst, NC Medical Doctor

NPI 1841234887 CMS profile 356646

205 Page Rd, Pinehurst, NC 28374

Open in the dashboard

General payments

$579,344

1,119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,067,222 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick Simpson of Pinehurst, NC is reported in the CMS Open Payments database as having received $579,344 across 1,119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,067,222 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50,667 125
2024 General $85,172 192
2023 General $75,773 163
2022 General $49,842 118
2021 General $61,805 98
2020 General $81,039 121
2019 General $175,046 302

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Simpson
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Patrick Simpson were reported at $50,667. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Patrick Simpson Interventional Cardiology median Middle half National median
2019 $175,046 $1,097 $329–$3,048 $163
2020 $81,039 $473 $161–$1,480 $114
2021 $61,805 $677 $233–$1,827 $132
2022 $49,842 $978 $333–$2,724 $149
2023 $75,773 $1,136 $382–$2,986 $160
2024 $85,172 $1,181 $395–$3,326 $164
2025 $50,667 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $173,968 166 payments
  2. Lilly USA, LLC $160,006 172 payments
  3. Novartis Pharmaceuticals Corporation $59,598 72 payments
  4. Boston Scientific Corporation $51,455 172 payments
  5. AstraZeneca Pharmaceuticals LP $48,334 98 payments
  6. Sanofi-Aventis U.S. LLC $36,586 40 payments
  7. Esperion Therapeutics, Inc. $23,498 22 payments
  8. Regeneron Healthcare Solutions, Inc. $10,456 22 payments
  9. Merck Sharp & Dohme Corporation $3,194 13 payments
  10. Abbott Laboratories $1,426 31 payments
  11. Other $10,822 311 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $483,071 234 payments
  2. Travel and Lodging $57,239 152 payments
  3. Food and Beverage $27,202 723 payments
  4. Consulting Fee $11,780 4 payments
  5. Education $52 6 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $136,204 143 payments
  2. JARDIANCE Diabetes $135,449 130 payments
  3. ENTRESTO $59,566 70 payments
  4. WATCHMAN Access System $44,421 69 payments
  5. JARDIANCE Diabetes $38,519 36 payments
  6. PRALUENT $36,416 31 payments
  7. BRILINTA $31,686 53 payments
  8. NEXLETOL $23,498 22 payments
  9. NEXLIZET $23,491 21 payments
  10. FARXIGA $16,537 38 payments
  11. Other $45,824 544 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,386

Median for Interventional Cardiology: 2,236

Drug cost

$480,425

Median for Interventional Cardiology: $380,412

Branded share of claims

38.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 115 $115,853
Eliquis Apixaban Brand 138 $115,392
Entresto Sacubitril/Valsartan Brand 81 $74,893
Jardiance Empagliflozin Brand 67 $54,067
Brilinta Ticagrelor Brand 57 $31,256
Multaq Dronedarone Hcl Brand 33 $28,102
Farxiga Dapagliflozin Propanediol Brand 28 $24,155
Repatha Sureclick Evolocumab Brand 17 $10,180
Praluent Pen Alirocumab Brand 12 $5,906
Ranolazine Er Ranolazine Brand 43 $2,859

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 140 billing codes

Paid by Medicare

$232,605

Of which drugs: $658

Medicare patients

1,348

Average age 76

Services billed

11,118

629 women, 719 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 52%
Diabetes 37%
Chronic kidney disease 37%
Heart failure 36%
Atrial fibrillation 36%
COPD 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 58 5,580 $539

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$56,426 67 —
FUROSCIX
$202 — —
Arcalyst
$186 — —
XARELTO
$166 115 —
MULTAQ
$76 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

1,119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record